MARATTO

article · Journal of Advanced Pharmaceutical Sciences

The Antiangiogenic Activity of Anti-IL-6 and Anti-IL-8 in the Tumor Microenvironment of Breast Cancer (Preclinical Study)

Abstract

The tumor microenvironment of breast cancer is considered a vibrant, multifactorial milieu that contains different cell subsets that shape the tumor fate. In addition, cytokines play a vital role within the tumor microenvironment, where different cytokines can promote inflammation, angiogenesis, and immune suppression. Interleukin-8 (IL-8) and Interleukin-6 (IL-6) are two of the most important cytokines that aid tumor progression and metastasis. Thus, this study aimed to compare the anti-angiogenic actions of neutralizing antibodies against IL-8 and IL-6. Tumor tissues from 30 patients having mastectomy supplemented with either monoclonal neutralizing antibodies against IL-8 or IL-6 were used to evaluate their antiangiogenic effect by evaluating (Vascular endothelial growth Factor) VEGF expression and microvessels count. It was demonstrated that Anti-IL-8 mAb declined significantly the number of microvessels in the tumor tissues compared to Anti-IL-6 and the control tissue cultures p<0.0001. In addition, the decrease in the microvessels count was insignificant within the untreated normal tissues (p=0.46). Therefore, the antiangiogenic activity of Anti-IL-8 monoclonal antibody is more potent than Anti-IL-6 according to the study conditions.

Research topics

  • Angiogenesis and VEGF in Cancer
  • Chemokine receptors and signaling
  • Cytokine Signaling Pathways and Interactions

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.21608/japs.2024.287068.1025

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.